Drug Discovery Automation - HCS & Cell Based Assays Symposiums

Philip Gribbon CSO, Fraunhofer IME

Models and Initiatives for Collaborations between Academia and Industry in Drug Discovery

Pre-Conference Symposium of the European Lab Automation 2012, Hamburg 

Date: May 29th 2012
Time: 13:30 pm to 17:30 pm
Location: Radisson Blu Hotel, Hamburg
Registration: Free of charge

Agenda

The symposium will give examples of the beneficial partnership models between Academia and the Pharmaceutical Industry by highlighting some of the positive outcomes of their joint research efforts. We will hear how this new collaborative trend drives innovation in Pharmaceutical Research and question its sustainability. 

Preliminary Agenda
• Academic Screening and the NIH roadmap in the US by Hakim Djaballah, Director, Memorial Sloan-Kettering Cancer Center
• Overview of the situation in Europe by Philip Gribbon, CSO, European Screening Port
• 6 invited talks 
• Panel discussion   

Confirmed Speakers:
- Catherine Kettleborough, Associate Director, MRCT Centre for Therapeutics Discovery UK
Talk Title: MRC Technology: Discovering Novel Drugs with Academia

- Bahne Stechmann, Scientific Manager, EU-OPENSCREEN
Talk Title: EU-OPENSCREEN - A European Infrastructure of Open Screening Platforms for Chemical Biology

- Bert Klebl, Managing Director & Chief Scientific Officer, Lead-Discovery-Center
Talk Title: LDC – Max-Planck’s Hybrid Collaboration Model for Small Molecule Based Drug Discovery

- Carole Fages, Head of the E2C Business Development Office, Sanofi
Talk Title: Sanofi Access Platform: A New Way of Partnering

- Matthias Gottwald, Vice President Research Policy & Collaborations, Bayer Pharma AG
Talk Title: EU Lead Factory – An Example of Bayer’s Activities in the Innovative Medicines Initiative IMI

- Anton Ussi, Head of Operations, EATRIS European Infrastructure for Translational Research
Talk Title: Bridging the Divide - Seeking Effective Translation Together with Academia